Blueshift Asset Management, LLC Vertex Pharmaceuticals Inc Transaction History

Blueshift Asset Management, LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	BUY	$285.76 - $321.48 $360,914 - $406,029	1,263 New	1,263 $364,000
Q4 2021 Feb 11, 2022	SELL	$177.01 - $223.45 $1.71 Million - $2.16 Million	-9,671 Closed	0 $0
Q3 2021 Nov 12, 2021	BUY	$181.39 - $202.99 $680,031 - $761,009	3,749 Added 63.31%	9,671 $1.75 Million
Q2 2021 Aug 13, 2021	BUY	$187.49 - $221.1 $360,730 - $425,396	1,924 Added 48.12%	5,922 $1.19 Million
Q1 2021 May 06, 2021	BUY	$207.02 - $241.31 $827,665 - $964,757	3,998 New	3,998 $859,000
Q4 2019 Feb 14, 2020	SELL	$166.71 - $223.91 $494,128 - $663,669	-2,964 Closed	0 $0
Q3 2019 Nov 12, 2019	BUY	$166.23 - $187.09 $492,705 - $554,534	2,964 New	2,964 $502,000

1,707

226M

1.2M

1.59M

Ticker VRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 256,691,008
Market Cap $122B
Description
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...

Get notified when there are updates to the investment portfolio of Blueshift Asset Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Blueshift Asset Management, LLC with notifications on news.